What question did this study set out to answer?

This study aims to compare the efficacy of Ustekinumab, Tofacitinib, and Upadacitinib in patients with ulcerative colitis who have previously failed advanced therapies.

January 23, 2026Journal of Crohn s and Colitis

P0625TRIDENT-UC Study: Higher Efficacy Medication in Bio-Exposed Ulcerative Colitis Patients

View Full Paper

Ask AI

Bookmark

This study aims to compare the efficacy of Ustekinumab, Tofacitinib, and Upadacitinib in patients with ulcerative colitis who have previously failed advanced therapies.
Conducted a retrospective analysis involving 312 ulcerative colitis patients across 9 centers.
Patients were divided into three treatment groups: Ustekinumab, Tofacitinib, and Upadacitinib.
Assessed outcomes at 16 and 52 weeks focusing on steroid-free clinical remission and endoscopic remission.
Utilized multivariable models to adjust for demographics, disease activity, and prior treatments.
At week 16, Upadacitinib had 4 times higher odds of achieving steroid-free clinical remission compared to Ustekinumab.
At week 52, Upadacitinib maintained 3 times higher odds of remission than both Ustekinumab and Tofacitinib.
Upadacitinib achieved higher rates of endoscopic remission compared to the other medications at both weeks.
In subanalysis, Upadacitinib showed superior outcomes after anti-TNF failure compared to the other therapies.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Retrospective multicentre study finds Upadacitinib achieves superior remission in ulcerative colitis patients, suggesting it may be a preferred option.

Cite This Study

Neves et al. (2026) studied this question.

synapsesocial.com/papers/69730f9fc8125b09b0d1f69a https://doi.org/10.1093/ecco-jcc/jjaf231.806

View Full Paper

Ask AI

Bookmark

Implication

Retrospective multicentre study finds Upadacitinib achieves superior remission in ulcerative colitis patients, suggesting it may be a preferred option.

P0625TRIDENT-UC Study: Higher Efficacy Medication in Bio-Exposed Ulcerative Colitis Patients

Key Points

Discussion

Implication

Cite This Study

P0625TRIDENT-UC Study: Higher Efficacy Medication in Bio-Exposed Ulcerative Colitis Patients

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider